Vaso-Occlusive Crisis Associated With Sickle Cell Disease Pipeline Review, H2 2018 – ResearchAndMarkets.com

DUBLIN–(BUSINESS WIRE)–The “Vaso-Occlusive
Crisis Associated With Sickle Cell Disease – Pipeline Review, H2 2018”

drug pipelines has been added to ResearchAndMarkets.com’s
offering.

Vaso-Occlusive Crisis Associated With Sickle Cell Disease – Pipeline
Review, H2 2018, provides comprehensive information on the therapeutics
under development for Vaso-Occlusive Crisis Associated With Sickle Cell
Disease (Cardiovascular), complete with analysis by stage of
development, drug target, mechanism of action (MoA), route of
administration (RoA) and molecule type. The guide covers the descriptive
pharmacological action of the therapeutics, its complete research and
development history and latest news and press releases.

The Vaso-Occlusive Crisis Associated With Sickle Cell Disease
(Cardiovascular) pipeline guide also reviews of key players involved in
therapeutic development for Vaso-Occlusive Crisis Associated With Sickle
Cell Disease and features dormant and discontinued projects. The guide
covers therapeutics under Development by Companies /Universities
/Institutes, the molecules developed by Companies in Phase III, Phase
II, Phase I, IND/CTA Filed, Preclinical and Unknown stages are 3, 4, 1,
1, 1 and 1 respectively.

Vaso-Occlusive Crisis Associated With Sickle Cell Disease
(Cardiovascular) pipeline guide helps in identifying and tracking
emerging players in the market and their portfolios, enhances decision
making capabilities and helps to create effective counter strategies to
gain competitive advantage.

Key Topics Covered:

  1. Introduction
  2. Report Coverage
  3. Vaso-Occlusive Crisis Associated With Sickle Cell Disease – Overview
  4. Vaso-Occlusive Crisis Associated With Sickle Cell Disease –
    Therapeutics Development
  5. Pipeline Overview
  6. Pipeline by Companies
  7. Products under Development by Companies
  8. Vaso-Occlusive Crisis Associated With Sickle Cell Disease –
    Therapeutics Assessment
  9. Assessment by Target
  10. Assessment by Mechanism of Action
  11. Assessment by Route of Administration
  12. Assessment by Molecule Type
  13. Vaso-Occlusive Crisis Associated With Sickle Cell Disease – Companies
    Involved in Therapeutics Development
  • Asklepion Pharmaceuticals LLC
  • AstraZeneca Plc
  • Bristol-Myers Squibb Co
  • Gilead Sciences Inc
  • Global Blood Therapeutics Inc
  • Modus Therapeutics AB
  • Novartis AG
  • NuvOx Pharma LLC
  • Pfizer Inc
  • Prolong Pharmaceuticals LLC
  • Seattle Genetics Inc

For more information about this drug pipelines report visit https://www.researchandmarkets.com/research/rwfgtn/vasoocclusive?w=4

Contacts

ResearchAndMarkets.com
Laura Wood, Senior Press Manager
press@researchandmarkets.com
For
E.S.T Office Hours Call 1-917-300-0470
For U.S./CAN Toll Free Call
1-800-526-8630
For GMT Office Hours Call +353-1-416-8900
Related
Topics: Hematological
Drugs

leverton

I have been involved with publishing and marketing for the past 32 years. My passion is helping people share their voice. I am able to do this through two important venues: One, with Area-Info.net where people can share everything from opinions to events to news. It is your choice! What do you want to share? Two, through a new program called America's Real Deal I am involved with to help business owners get their voice heard.I schedule speaking engagements with community groups and business groups to share my passion about the importance of "sharing your voice".Contact me directly at lee@leeeverton.coom for scheduling information.